Search Results - "King, Madeline A"

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii by Alosaimy, Sara, Morrisette, Taylor, Lagnf, Abdalhamid M, Rojas, Leonor M, King, Madeline A, Pullinger, Benjamin M, Hobbs, Athena L V, Perkins, 3rd, Nicholson B, Veve, Michael P, Bouchard, Jeannette, Gore, Tristan, Jones, Bruce, Truong, James, Andrade, Justin, Huang, Glen, Cosimi, Reese, Kang-Birken, S Lena, Molina, Kyle C, Biagi, Mark, Pierce, Michael, Scipione, Marco R, Zhao, Jing J, Davis, Susan L, Rybak, Michael J

“…Forty-six patients were treated with eravacycline (ERV) for Acinetobacter baumannii infections, where 69.5% of isolates were carbapenem resistant (CRAB)…”
Get full text

Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022 by Kunz Coyne, Ashlan J, Alosaimy, Sara, Lucas, Kristen, Lagnf, Abdalhamid M, Morrisette, Taylor, Molina, Kyle C, DeKerlegand, Alaina, Schrack, Melanie Rae, Kang-Birken, S Lena, Hobbs, Athena L V, Agee, Jazmin, Perkins, 3rd, Nicholson B, Biagi, Mark, Pierce, Michael, Truong, James, Andrade, Justin, Bouchard, Jeannette, Gore, Tristan, King, Madeline A, Pullinger, Benjamin M, Claeys, Kimberly C, Herbin, Shelbye, Cosimi, Reese, Tart, Serina, Veve, Michael P, Jones, Bruce M, Rojas, Leonor M, Feehan, Amy K, Scipione, Marco R, Zhao, Jing J, Witucki, Paige, Rybak, Michael J

“…The rise of multidrug-resistant (MDR) pathogens, especially MDR Gram-negatives, poses a significant challenge to clinicians and public health. These resilient…”
Get full text

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study by Gallagher, Jason C, Satlin, Michael J, Elabor, Abdulrahman, Saraiya, Nidhi, McCreary, Erin K, Molnar, Esther, El-Beyrouty, Claudine, Jones, Bruce M, Dixit, Deepali, Heil, Emily L, Claeys, Kimberly C, Hiles, Jon, Vyas, Nikunj M, Bland, Christopher M, Suh, Jin, Biason, Kenneth, McCoy, Dorothy, King, Madeline A, Richards, Lynette, Harrington, Nicole, Guo, Yi, Chaudhry, Saira, Lu, Xiaoning, Yu, Daohai

“…Multidrug-resistant infections remain common in hospitals worldwide. We investigated the outcomes associated with the use of ceftolozane-tazobactam for the…”
Get full text

Early Experience With Eravacycline for Complicated Infections by Alosaimy, Sara, Molina, Kyle C, Claeys, Kimberly C, Andrade, Justin, Truong, James, King, Madeline A, Pullinger, Benjamin M, Huang, Glen, Morrisette, Taylor, Lagnf, Abdalhamid M, Davis, Susan L, Rybak, Michael J

“…Abstract Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was Klebsiella pneumoniae, and 30-day survival was 74%…”
Get full text

A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections by Hart, Delaney E, Gallagher, Jason C, Puzniak, Laura A, Hirsch, Elizabeth B

“…Abstract Background Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study…”
Get full text